Navigation Links
Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity
Date:5/31/2011

MOUNTAIN VIEW, Calif., May 31, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts were presented over the weekend at the European Congress on Obesity (ECO) in Istanbul, Turkey.  ECO is the official obesity congress of The European Association for the Study of Obesity (EASO). ECO is regularly attended by more than 2500 participants from over 75 countries and is considered to be the most important annual scientific event on obesity in Europe.  

Highlights from the ECO presentations were as follows:

A poster presentation authored by W. Timothy Garvey, MD from the University of Alabama at Birmingham reported reductions in progression to type 2 diabetes and improvement in glycemic status in CONQUER patients that were ADA-defined as prediabetics at baseline.  Of the 2,487 patients in the CONQUER study, 1,119 were determined to have prediabetes.  In the prediabetics treated with QNEXA, hemoglobin A1c, fasting glucose and fasting insulin were significantly improved at week 56 (ITT-LOCF p<0.005 vs. placebo).  In the prediabetic population significantly more QNEXA treated patients achieved normal blood sugar levels (p=0.0016) and significantly more patients on placebo were progressed to type 2 diabetics as compared to the QNEXA treated patients (p=0.0253).  

"For this set of patients, QNEXA treatment led to benefits above and beyond losing weight.  The results highlighted by Dr Garvey showed that weight loss after 56 weeks of treatment led to an improvement in glycemic status and reduction of progression to type 2 diabetes.  This clinically important finding further strengthens the QNEXA benefit profile," added Barbara Troupin, MD, senior director of medical affairs for VIVUS.  

The CONQUER study included 2,487 patients that had two or more comorbidities studied over 56 weeks. 
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Hope Paige Designs Medical ID Bracelets Now Available in 1,100 Additional Locations
2. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
3. Omeros Reports Allowance of Additional Patent for Arthroscopic Product
4. Cynosure Receives Additional International Regulatory Approvals for New Cellulite Reduction Workstations
5. Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
6. Rosetta Genomics Announces Issuance of Additional U.S. Patent
7. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
8. Johnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck
9. Southern Home Medical Equipment Reports Additional Revenues and Profits for 2010
10. Additional 8 Products of DK Sinopharma, Inc. are Included in 2010 Provincial Medical Insurance Catalogs in 4 Separate Provinces in the Peoples Republic of China
11. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... STAAR Surgical Company (NASDAQ: STAA ), a leading developer, ... the eye, today announced that its Board of Directors has ... Mr. Wall was formerly the General Counsel ... firm, for more than nine years. Mr. Wall is currently ... the Corporate Governance Committee and member of the Audit Committee, ...
(Date:9/2/2015)... and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ) has announced the addition of ... November 26-27, 2015)" conference to their offering. ... key areas of pharmaceutical regulatory affairs in China ... Macau and Taiwan and ... gaining and maintaining a successful Marketing Authorisation in the region ...
(Date:9/2/2015)... OAKS, Calif. , Sept. 2, 2015 /PRNewswire/ ... the submission of a Marketing Authorization Application (MAA) ... centralized procedure for etelcalcetide (formerly AMG 416) for ... patients with chronic kidney disease (CKD) on hemodialysis ... calcimimetic agent that can be administered intravenously. ...
Breaking Medicine Technology:William P. Wall Appointed to STAAR Surgical Board of Directors 2Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7
... loss of Arf gene in presence of BCR-ABL ... of the bone,marrow, helping cells develop immunity to ... 29 Results of a study,by investigators at ... why the drug imatinib (Gleevec(TM)), which has revolutionized,the ...
... from Roche-, MONTVALE, N.J., Aug. 29 ... the dosing of the,first subject in the single ... program of R4996/MEM 63908, a partial agonist of ... could be beneficial in,the treatment of Alzheimer,s disease ...
Cached Medicine Technology:St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia 2Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908 2Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908 3
(Date:9/2/2015)... ... 2015 , ... RxNT , an innovative software solutions ... cloud-based mobile ePrescribing application. The release of this enhanced iPhone app marks the ... in health technology, RxNT was one of the first to build an ePrescribing ...
(Date:9/2/2015)... Schwerzenbach, Switzerland (PRWEB) , ... September 02, 2015 ... ... quality control of incoming goods, intermediate or final products. Automating sample handling makes ... and automated sample handling, showing each step of the automated workflow and the ...
(Date:9/2/2015)... ... September 02, 2015 , ... A UPMC ... has earned international recognition as a premier center for treatment of and research ... catastrophic internal bleeding and stroke. , Cure HHT, previously known as The ...
(Date:9/2/2015)... ... September 02, 2015 , ... Ericson is a noted speaker and educator ... and Associate Director of Education for the Association for Clinical Documentation Improvement Specialists (ACDIS) ... CDI Boot Camps. She serves as a CDI subject matter expert for a variety ...
(Date:9/2/2015)... ... September 02, 2015 , ... The 2015 China ... international investment and business conference will be hosted at five star Beijing Kunlun ... full-weekend networking conference will feature leading EB-5 industry professionals and Chinese private equity ...
Breaking Medicine News(10 mins):Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2
... Inc. (Nasdaq: MYL ) today announced that ... its delisting offer for the publicly held shares of ... ingredient manufacturer in which Mylan acquired a controlling interest ... rupees per share, which was established by the reverse ...
... George Tiller is an abhorrent act of violence, and his ... moment. Federal law enforcement is coordinating with local law ... and I have directed the United States Marshals Service to ... nation. The Department of Justice will work to bring ...
... (May 31, 2009)Fox Chase Cancer Center investigators report that ... metastatic kidney cancer in a phase I trial. Early ... may be active in patients with rare forms of ... to other targeted therapies. , Elizabeth Plimack, M.D., M.S., ...
... MAY 31, 2009 The American Society for ... of endoscopy during the fifth annual ASGE Crystal Awards on ... this year,s event will begin at 6:30 p.m. at Navy ... Disease Week (DDW), the ASGE Crystal Awards symbolize the finest ...
... to start San Francisco-to-Los Angeles ride May 31SAN FRANCISCO ... bicyclists from 41 states and 14 nations will stream ... to Los Angeles as participants in the colorful and ... trek is expected to raise $10.5 million to support ...
... PITTSBURGH, May 30 Patients undergoing treatment for advanced ... addition of gefinitib to chemotherapy, according to a study ... by Ethan Argiris, M.D., associate professor of medicine, University ... Head and Neck Cancer Program of the University of ...
Cached Medicine News:Health News:Mylan Announces Successful Matrix Delisting Offer 2Health News:2-drug combination appears safe and active in metastatic kidney cancer 2Health News:ASGE and ASGE Foundation hold Crystal Awards Dinner as part of Digestive Disease Week 2Health News:ASGE and ASGE Foundation hold Crystal Awards Dinner as part of Digestive Disease Week 3Health News:ASGE and ASGE Foundation hold Crystal Awards Dinner as part of Digestive Disease Week 4Health News:ASGE and ASGE Foundation hold Crystal Awards Dinner as part of Digestive Disease Week 5Health News:ASGE and ASGE Foundation hold Crystal Awards Dinner as part of Digestive Disease Week 6Health News:ASGE and ASGE Foundation hold Crystal Awards Dinner as part of Digestive Disease Week 7Health News:AIDS/LifeCycle 8 to Raise $10.5 Million to Fight AIDS 2Health News:AIDS/LifeCycle 8 to Raise $10.5 Million to Fight AIDS 3Health News:AIDS/LifeCycle 8 to Raise $10.5 Million to Fight AIDS 4Health News:New treatment combination proves safe for head and neck cancer patients 2
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures....
... Bio Vortex Adapter in conjunction with the Vortex ... Using the Mo Bio Vortex Adapter is an ... Prep machines which offer the same technology. ... tubes at one time and will fit any ...
... V-500 with Vacuum Controller V-800 and water-cooled secondary ... Compact Housing Model V-500 ... to handle most vacuum applications. Applications ... two rotary evaporators Laboratory vacuum source ...
... V-500 with Vacuum Controller V-800 and water-cooled secondary ... Model V-500 is a powerful ... vacuum applications. Applications Ideally suited ... Laboratory vacuum source for instruments including ...
Medicine Products: